Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Immunologic Memory”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources

Evolution of CD4 T-cell subsets following infection of naive and memory immune mice with Mycobacterium tuberculosis.

We report here that during the course of an experimental infection of mice with Mycobacterium tuberculosis, the differential expression of the cell surface antigens CD44 and CD45RB could be used to delineate CD4+ T cells into four phenotypically distinct subsets. The major subset present was designated CD44lo/CD45RBhi and is associated with naive or resting T cells. The three remaining subsets expressed increased levels of the CD44 antigen as the infection progressed and could therefore be considered to be in an activated state. These activated populations could be further divided on the basis of their variable expression of the CD45RB antigen. These populations were designated CD44hi/CD45RBhi, CD44hi/CD45RBlo, and CD44hi/CD45RBneg. Kinetic studies of the emergence of these populations indicated that these subsets arose sequentially from the naive population at times associated with the peak expression of acquired specific resistance. In further studies, in an attempt to associate either the CD44hi/CD45RBlo or the CD44hi/CD45RBneg population with acquired immunologic memory of tuberculosis infection, draining lymph nodes of challenged memory immune animals were analyzed for the accumulation of the CD4+ subsets. The accumulation of both the CD44hi/CD45RBlo and the CD44hi/CD45RBneg populations was observed, but the CD44hi/CD45RBlo population was enriched in a manner consistent with the rapid accumulation of memory T cells during the anamnestic response. While functional roles for each of these subsets remain to be determined, these data provide the first evidence for the evolution of multiple, phenotypically distinct CD4+ T-cell subsets during the in vivo response to an experimental mycobacterial infection.

Animals↗

Very low dose hepatitis B vaccination in the newborn: anamnestic response to booster at four years.

Seventy-eight children who had received three very low doses (1 or 2 microg) of Merck, Sharp and Dohme (MSD) plasma-derived vaccine (PDV) in early infancy were followed to approximately four years of age. Of the 70 who had responded to the initial course of vaccine with measurable anti-HBs, levels had fallen to below 10 mlU/ml in 38% of subjects given 1 microg doses and in 17% of those who had been given 2 microg doses. None of the children were positive for anti-HBc. Two weeks after 2 microg dose of MSD recombinant DNA (rDNA) vaccine all subjects had more than 10 mlU/ml of anti-HBs, with 90% exceeding 1,000 mlU/ml. A response to hepatitis B vaccine in infancy is followed by an effective immunological memory for several years, even if anti-HBs falls to low levels. The rDNA hepatitis B vaccine (MSD) in 2 microg doses is an effective booster following a primary course of plasma derived vaccine.

Child, Preschool↗

Antigenic selection of IgG precursor subpopulations.

The temporal increase in the antigen-binding characteristic of the IgG antibody synthesized after primary immunization is thought to result from antigen preferentially selecting those precursors of the antibody-forming cells with higher affinity receptors. We have investigated this regulatory role of antigen on the selection and expression of IgG precursor subpopulations in rabbit lymph node populations undergoing the secondary anti-bovine serum albumin (BSA) response in vitro. The data indicate that although immunologic memory increased between 1 and 4 months after immunization there was not an increase in antigen sensitivity. We also determined the avidity of the IgG antibody secreted by PFC elicited in the cell cultures. Although the avidity of antibody secreted by PFC elicited with low concentrations of antigen was 2-fold greater than when high concentrations of antigen were employed, analyses of the avidity subpopulations of IgG PFC revealed that memory potential was not restricted to high affinity-primed cells. Moreover, populations of PFC that gave differing avidity values were similar in terms of their plaque diameters and IgG secretion rates.

Animals↗

Humoral response and memory formation in carp after injection of Aeromonas hydrophila bacterin.

The humoral immune response of carp (Cyprinus carpio) upon a bacterial fish pathogen Aeromonas hydrophila was studied in relation to memory formation. After a single intramuscular (i.m.) injection of formalin killed A. hydrophila cells (F-Ah), maximum serum Ab (Ab) titers were observed at day 20. Distinct titers were still seen at day 360 in the groups injected with a medium or high antigen (Ag) dose (10(7) respectively 10(9) F-Ah). The effect of a second immunization with a high Ag dose was studied in fish primed 1, 3, 8 or 12 months earlier with 10(5), 10(7) or 10(9) F-Ah. The height of the secondary Ab response was positively correlated with the height of the priming Ag dose. Challenge with a low Ag dose (10(6) F-Ah) gave the best results with 10(7) F-Ah primed animals. The highest secondary responses were obtained with combinations of corresponding priming and challenge dosages. It is concluded that fish are able to form immunological memory to this bacterial Ag. However, optimal memory levels are reached after a relative long period (3-8 months).

Aeromonas↗

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis, using yellow fever (YF) 17D vaccine as a vector. In a double-blind phase 2 trial, 99 adults received vaccine, placebo, or YF 17D vaccine (YF-VAX). ChimeriVax-JE was well tolerated, with no differences in adverse events between treatment groups. Viremias resulting from administration of ChimeriVax-JE and YF-VAX were of short duration and low titer; 82 (94%) of 87 subjects administered graded doses (1.8-5.8 log(10)) of ChimeriVax-JE developed neutralizing antibodies. A second dose, administered 30 days later, had no booster effect. Previous inoculation with YF did not interfere with ChimeriVax-JE, but there was a suggestion (not statistically significant) that ChimeriVax-JE interfered with YF-VAX administered 30 days later. A separate study explored immunological memory both in subjects who had received ChimeriVax-JE 9 months before and in ChimeriVax-JE-naive subjects challenged with inactivated mouse-brain vaccine (JE-VAX). Anamnestic responses were observed in preimmune individuals. ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose.

Animals↗

Differential splicing of antigen-encoding RNA reduces endogenous epitope presentation that regulates the expansion and cytotoxicity of T cells.

The activation of CTLs is dependent on the recognition of MHC-bound peptide present on the surface of APCs. We give evidence in this study that differential splicing of Ag-encoding RNA can decrease the antigenic dose in APCs and regulate the recall of human memory CTLs. Differential splicing of RNA that encoded an immunodominant HLA-B8-restricted CTL epitope of EBV reduced the functional presentation of this epitope, and consequently the in vitro expansion and activity of CTLs, as measured by MHC/peptide-tetramer staining and cytotoxicity assays. The reduced activity of the stimulated CTLs was not only due to lower numbers of Ag-specific CTLs but, surprisingly, was also characterized by decreased cytotoxicity of the CTLs to target cells presenting limiting amounts of the peptide epitope. As indicated by TCR repertoire analysis, the reduction in CTL activity was not caused by stimulation of distinct populations of TCR clonotypes. This study demonstrates how a common eukaryotic posttranscriptional mechanism of gene regulation can modulate the endogenous presentation of Ag and ultimately contribute to the fine tuning of immunological memory cells, which are important in the fight against pathogens and tumors and in autoimmunity.

Alternative Splicing↗

Immunology of vaccination.

An ideal vaccine is relatively easy to define, but few real vaccines approach the ideal and no vaccines exist for many organisms, for which a vaccine is the only realistic protective strategy in the foreseeable future. Many difficulties account for the failure to produce these vaccines. All micro-organisms deploy evasion mechanisms that interfere with effective immune responses and, for many organisms, it is not clear which immune responses provide effective protection. However, recent advances in methods for studying immune response to pathogens have provided a better understanding of immune mechanisms, including immunological memory, and led to the realisation that the initiation of immune responses is a key event requiring triggering through 'danger' signals. Based on these findings, the development of novel adjuvants, vectors and vaccine formulations allowing stimulation of optimal and prolonged protective immunity should lead to the introduction of vaccines for previously resistant organisms.

Humans↗

Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.

A candidate DNA vaccine expressing dengue virus type 1 pre-membrane and envelope proteins was used to immunize rhesus macaques. Monkeys were immunized intramuscularly (i.m.) or intradermally (i.d.) by three or four 1 mg doses of vaccine, respectively. Monkeys that were inoculated i.m. seroconverted more quickly and had higher antibody levels than those that were inoculated i.d. The sera exhibited virus-neutralizing activity, which declined over time. Four of the eight i.m.-inoculated monkeys were protected completely from developing viraemia when challenged 4 months after the last dose with homologous dengue virus. The other four monkeys had reduced viraemia compared with the control immunized monkeys. The i.d. -inoculated monkeys showed no reduction in viraemia when challenged with the virus. All vaccinated monkeys showed an anamnestic antibody response, indicating that they had established immunological memory. Vaccine-induced antibody had an avidity index similar to that of antibody induced by virus infection; however, no clear correlation was apparent between antibody avidity and virus neutralization titres.

Animals↗

Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.

Mice bearing disseminated syngeneic FBL-3 leukemia were treated with cyclophosphamide plus long term-cultured T cells immune to FBL-3. The cultured T cells for therapy had been induced to grow in vitro for 62 d by intermittent stimulation with irradiated FBL-3. At the time of therapy, such antigen-driven long term-cultured T cells were greatly expanded in number, proliferated in vitro in response to FBL-3, and were specifically cytotoxic. Following adoptive transfer, donor T cells persisting in the host were identified and counted using donor and host mice congenic for the T cell marker Thy-1. The results show that antigen-driven long term-cultured T cells proliferated rapidly in vivo, distributed widely in host lymphoid organs, and were effective in tumor therapy. Moreover, the already rapid in vivo growth rate of donor T cells could be augmented by administration of exogenous IL-2. When cured mice were examined 120 d after therapy, donor L3T4+ T cells and donor Lyt-2+ T cells could be found in large numbers in host ascites, spleen, and mesenteric and axillary lymph nodes. The persisting donor T cells proliferated in vitro, and became specifically cytotoxic in response to FBL-3, demonstrating that antigen-driven long term-cultured T cells can persist long term in vivo and provide immunologic memory.

Animals↗

Analysis of the kinetics of antiviral memory T help in vivo: characterization of short-lived cross-reactive T help.

To evaluate the kinetics of functional effector and memory T help in vivo the effect of priming with one serotype of vesicular stomatitis virus-Indiana (VSV-IND) on the antibody response to a serologically distinct heterologous second serotype (VSV-New Jersey: VSV-NJ) was studied. Mice primed with VSV-IND 4 or 8 days before being given a second infection of VSV-NJ developed an earlier and enhanced IgG response to neutralizing determinants of the second VSV serotype. However, this enhanced response was not detected in mice primed 15 or more days prior to a second infection. After 15 days, mice challenged with the heterologous VSV-NJ mounted a strictly normal primary response without evidence of suppression. It was shown by in vivo time-kinetics experiments that efficient VSV cross-reactive T help, capable of enhancing the IgG response is short lived and cyclosporin A resistant. Adoptive transfer experiments demonstrated in the absence of experimental evidence for suppression that this short-lived capacity to enhance neutralizing IgG antibody responses is mediated by T cells. These findings have implications for understanding antiviral protection and immunological memory against related but serologically distinct viruses.

Animals↗

Long term protection after hepatitis B vaccination.

A survey of persistence of anti-HBs after hepatitis B vaccination has shown that five years after vaccination on a sample of 152 persons, or 82.53%, stands at >10 IU/I. Long term immunogenicity of vaccinated children remained at 88.89%, health workers 79.41% and drug addicts 64.28%. The results of these studies in Bosnia and Herzegovina show the high level of protection hepatitis B vaccine against HBV infection. Vaccination against viral hepatitis B results in immunologic memory response among the vaccinated, and even after a decrease of anti-HB level following the third vaccine dose inoculation, a booster dose is not needed. Immunity remains steady and a booster dose is not recommended.

Adult↗

Effect of a nitrofuran derivative (AF2) on the immune response of mice.

The effect of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2), which had been widely used in Japan as a food preservative, on the immune response of mice was analyzed, since the drug has been known to reveal very potent mutagenicity but fairly weak carcinogenicity. Although AF-2 suppressed the primary immune response of mice under limited experimental conditions, in general, it augmented the immune response of mice, especially the production of immunological memory. It was found by hapten-carrier system that activities of both the T-cell lineage and the B-cell lineage were enhanced by the administration of AF-2, but the activation of the T-cell lineage seemed to be primary because the chemical did not affect the response of mice to a T cell-independent antigen epsilon-2,4-dinitrophenyl-L-lysyl-dextran T2000 (DNP50-dextran T2000). AF-2 did not prevent the suppressive effect of 7,12-dimethylbenza[a]anthracene (DMBA) on the immune response but it suppressed both the primary and the memory production in concert with DMBA, suggesting that the augmenting effect of AF-2 on the T-cell lineage may be in a different way from that of immunopotentiators such as lentinan.

9,10-Dimethyl-1,2-benzanthracene↗

Immunity to adult cestodes: basic knowledge and vaccination problems. A review.

Immunity in mammals to intestinal cestodes has been reviewed using the normal final host infected with the tapeworms Hymenolepis diminuta in rats and H. microstoma and H. nana in mice as a model. Primary infections up to a certain level continue to live as long the host, while most worms in infections with larger doses are destrobilated and expelled. It has been argued that concomitant immunity against a superimposed infection exists in rats and mice infected with H. diminuta and H. microstoma, respectively, and suggested that it also takes place in humans infected with Taenia spp. Immunity to secondary infections after expulsion of a primary infection occurs, but immunological memory is rather short-lived, although depression of worm growth occurs for at least two third of the rat's life. Serum antibodies have been shown to produce a direct precipitate on the surface of cestodes in vitro, but a direct effect of antibodies in vivo or the relationship with e.g. host effector cells, like mast cells and eosinophils, is unknown. It has been shown that peritoneal exudate cells from rats are able to kill H. diminuta in vitro. Very little is known about the mechanisms of tapeworms to counteract host immunological responses, but the tegumental glycoconjugates and discoidal secretory bodies are possible candidates. Passive transfer of immunity by mesenteric lymph node cells has only been successful using cells from H. nana egg-infected mice and has shown that only short-lived proliferating cells are responsible for transferring immunity. Vaccination procedures and problems are discussed with special reference to E. granulosus in dogs.

Animals↗

Production of antibodies to dextran using liposome as adjuvant.

The kinetics and nature of the immune response to dextran-BSA entrapped into liposomes was studied in rabbit. The antibody titer in the secondary immunization was found to be higher as compared to that in the primary response. In the primary response antibodies were of both IgG and IgM type but following secondary immunization the IgG level was increased. The conjugate entrapped into liposomes could establish an immunological memory for dextran. In order to eliminate the carrier effect of BSA, dextran was either entrapped or coupled to liposome and the immune response was studied in mice. The results revealed that dextran entrapped into liposomes or coupled to liposome surface induced IgM type immune response and antibody titer did not increase on secondary immunization.

Adjuvants, Immunologic↗

[Production of interferon and virus-neutralizing antibodies in adult mice infected with enteroviruses during the neonatal period].

Newborn albino mice were inoculated with enteroviruses and in 6 weeks reinfected with homologous or heterologous strains. Strains moderately pathogenic for newborn mice led to formation of specific immunologic memory. Mice infected after birth with highly pathogenic strains produced specific antibodies for a long time and lacked secondary response. Production of interferon was not associated either with the strain pathogenicity for newborn mice or with the presence of antibodies.

Animals↗

Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.

Using a novel orthotopic MBT-2 murine bladder tumor model, we evaluated the feasibility of intravesical gene therapy utilizing a cationic liposome, DMRIE/DOPE. Superficial bladder tumors were consistently established by intravesical instillation of 5x10(5) MBT-2 cells in syngeneic C3H female mice. In situ gene transfer to bladder tumors was accomplished via intravesical instillation of plasmid DNA/DMRIE/DOPE lipoplex. Beta-Galactosidase (beta-gal) gene expression was preferentially evident in bladder tumors and was present for at least 7 days after a single 30 min in situ transfection. Murine interleukin-2 (IL-2) gene was used for treatment of 3-day-old pre-established bladder tumors. Forty percent of animals treated with IL-2 gene were completely free of tumors by 60 days following the initial tumor implantation, while all control groups treated with beta-gal gene died. Those animals initially cured of pre-established tumors were completely resistant to a subsequent tumor re-challenge and their splenocyte-derived cytotoxic T lymphocytes were shown to be specific to MBT-2 cells, indicating that immunological memory against MBT-2 tumors was elicited by the treatment. These results demonstrate the possibility of an effective clinical application of this in situ intravesical IL-2 gene delivery system to high-risk superficial bladder tumors, obviating a need for tumor procurement and ex vivo gene transfer.

Administration, Intravesical↗

[Immunologic properties and role of the low-molecular component in a preparation of S. typhi Vi antigen].

The author compared the serological, immunogenic and protective activity of the Vi-antigen and its high- and low-molecular fractions; an interaction between these fractions in administration of their mixture to the animals was studied. The low-molecular antigen (the 2nd fraction), contained in the preparation of the Vi-polysaccharide differed considerably (by properties) from the high-molecular antigen. The 2nd fraction, whose antigenic substance possessed the least immunogenic and protective capacity, failed to induce or to resolve the immunological memory, and also prevented the manifestations of the high immunogenicity of the 1st fraction. Therefore the nonfractional preparation of the Vi-antigen, consisting of 80% of a high-molecular substance of the 1st fraction and having the same serological activity as the 1st fraction, possessed a lesser immunogenic and protective activity.

Animals↗

[Secondary immune response to flagellin conjugates with polyacrylic acid].

The conditions of the activation of immunological memory by means of flagellin and its conjugate with polyacrylic acid (PAA) have been studied. The flagellin-PAA conjugate has proved to be capable of inducing the appearance of memory cells when introduced in doses, considerably lower (0.01 and 0.001 micrograms) than those of native protein (0.1, 1 and 10 micrograms). At the same time no manifest differences in the reactivation of flagellin-induced and conjugate-induced memory cells by the antigen have been established. Immunization with protein, as well as with its conjugate, has been found to induce the formation of mainly anti-Hi : 1,2 IgG in secondary immune response.

Acrylic Resins↗